Renhe Pharmacy Co., Ltd.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE000000NF8
CNY
6.02
0.03 (0.5%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationQuarterly Results
Results Snapshot
YoYQoQ
Figures in Million
Consolidate Quarterly Results
Jun'25
Mar'25
Dec'24
Sep'24
Jun'24
Mar'24
Dec'23
Net Sales
979.22
978.03
910.96
776.28
1,115.15
1,226.02
1,200.51
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
979.22
978.03
910.96
776.28
1,115.15
1,226.02
1,200.51
Raw Material Cost
643.33
635.87
581.39
524.09
687.08
797.44
803.31
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
0.02
0.02
0.07
0.02
0.03
0.05
0.06
Selling and Distribution Expenses
134.64
166.51
179.03
139.53
156.03
248.78
156.11
Other Expenses
1.19
0.75
1.98
0.49
1.05
0.59
1.68
Total Expenditure (Excl Depreciation)
789.86
809.89
780.32
668.55
853.64
1,052.16
976.33
Operating Profit (PBDIT) excl Other Income
189.4
168.1
130.6
107.69999999999999
261.5
173.9
224.20000000000002
Other Income
24.14
81.18
58.62
34.82
16.33
91.43
22.94
Operating Profit (PBDIT)
243.14
278.97
110.29
176.93
306.01
293.87
61.00
Interest
0.02
0.02
0.07
0.02
0.03
0.05
0.06
Exceptional Items
0.06
-0.02
16.75
0.23
-0.10
-0.85
17.10
Gross Profit (PBDT)
335.89
342.17
329.57
252.19
428.08
428.58
397.19
Depreciation
29.59
29.59
34.18
34.18
28.57
28.57
36.99
Profit Before Tax
213.58
249.34
92.80
142.97
277.31
264.40
41.04
Tax
54.27
51.64
39.57
39.47
74.40
54.60
63.31
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
126.12
164.31
66.23
78.50
159.88
177.30
26.88
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
126.12
164.31
66.23
78.50
159.88
177.30
26.88
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
32.39
32.43
-14.55
23.69
43.03
32.50
-50.07
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
158.51
196.74
51.68
102.20
202.91
209.80
-23.18
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
1.0
1.0
1.0
1.0
1.0
1.0
1.0
Reserves
6,264.55
6,342.03
6,173.66
6,097.67
6,292.50
6,130.40
5,993.04
Earnings per share (EPS)
0.09
0.12
0.05
0.06
0.12
0.13
0.02
Diluted Earnings per share
0.09
0.12
0.05
0.06
0.12
0.13
0.02
Operating Profit Margin (Excl OI)
19.34%
17.2%
1.92%
13.9%
23.42%
14.18%
0.09%
Gross Profit Margin
24.83%
28.52%
13.94%
22.82%
27.43%
23.9%
6.5%
PAT Margin
12.88%
16.8%
7.27%
10.11%
14.34%
14.46%
2.24%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - QoQ
stock-summary

Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.12% vs 7.35% in Mar 2025

stock-summary

Consolidate Net Profit

QoQ Growth in quarter ended Jun 2025 is -19.42% vs 280.46% in Mar 2025

stock-summary

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Jun 2025 is 10.72% vs 282.59% in Mar 2025

stock-summary

Interest

No Interest in the last few periods

stock-summary

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Jun 2025 has improved from Mar 2025

Compare Quarterly Results Of Renhe Pharmacy Co., Ltd. With
Markets Mojo
Figures in Million
Consolidate Quarterly Results
Markets Mojo
Markets Mojo
Change(CNY)
Change(%)
Net Sales
979.22
0
979.22
Other Operating Income
0.00
0.00
0.00
Total Operating income
979.22
0
979.22
Raw Material Cost
643.33
0
643.33
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
0.02
0
0.02
Selling and Distribution Expenses
134.64
0
134.64
Other Expenses
1.19
0.00
1.19
Total Expenditure (Excl Depreciation)
789.86
0
789.86
Operating Profit (PBDIT) excl Other Income
189.36
0.00
189.36
Other Income
24.14
0
24.14
Operating Profit (PBDIT)
243.14
0
243.14
Interest
0.02
0
0.02
Exceptional Items
0.06
0
0.06
Gross Profit (PBDT)
335.89
0
335.89
Depreciation
29.59
0
29.59
Profit Before Tax
213.58
0
213.58
Tax
54.27
0
54.27
Provisions and contingencies
0
0
0.00
Profit After Tax
126.12
0
126.12
Extraordinary Items
0.00
0
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
126.12
0
126.12
Share in Profit of Associates
0
0
0.00
Minority Interest
32.39
0
32.39
Other related items
0.00
0.00
0.00
Consolidated Net Profit
158.51
0
158.51
Equity Capital
0
0
0.00
Face Value
1.00
0
0.00
Reserves
6,264.55
0
6,264.55
Earnings per share (EPS)
0.09
0
0.09
Diluted Earnings per share
0.09
0
0.09
Operating Profit Margin (Excl OI)
19.34%
0%
0.00
19.34%
Gross Profit Margin
24.83%
0%
0.00
24.83%
PAT Margin
12.88%
0%
0.00
12.88%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Quarterly - Net Sales
Net Sales 97.92 Million
in Jun 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Jun 2025 is 0.12% vs 7.35% in Mar 2025

stock-summary

YoY Growth in quarter ended Jun 2025 is -12.20% vs -15.17% in Jun 2024

Quarterly - Consolidate Net Profit
Consolidate Net Profit 15.85 Million
in Jun 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Jun 2025 is -19.42% vs 280.46% in Mar 2025

stock-summary

YoY Growth in quarter ended Jun 2025 is -21.88% vs -2.92% in Jun 2024

Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 21.90 Million
in Jun 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Jun 2025 is 10.72% vs 282.59% in Mar 2025

stock-summary

YoY Growth in quarter ended Jun 2025 is -24.40% vs 13.47% in Jun 2024

Quarterly - Interest
Markets Mojo
No Interest in the last few periods
Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 19.34%
in Jun 2025

Figures in %
stock-summary

QoQ Growth in quarter ended Jun 2025 has improved from Mar 2025

stock-summary

YoY Growth in quarter ended Jun 2025 has fallen from Jun 2024